References
Schmidt J, Warrington K. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. Drugs Aging 2011; 28(8): 651–66
Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 2010 Aug; 49(8): 1594–7
Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010 Jan; 49(1): 186–90
Weyand C, Goronzy J. Giant cell arteritis, polymyalgia rheumatica, and Takayasu’s arteritis. In: Klippel J, Stone J, Crofford L, et al., editors. Primer on the rheumatic diseases. New York (NY): Springer, 2008: 398–409
Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of literature. Acta Ophthalmol Scand 2002 Aug; 80(4): 355–67
Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004 Oct 5; 141(7): 493–500
Rights and permissions
About this article
Cite this article
Corticosteroids are essential when treating patients with giant cell arteritis or polymyalgia rheumatica. Drugs Ther Perspect 28, 11–14 (2012). https://doi.org/10.2165/11208740-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11208740-000000000-00000